The combination of high-dose teriparatide and denosumab is most likely to help prevent fractures in postmenopausal women, the ANZBMS 30th Annual Scientific Meeting has been told. Presenting an update on combination therapy for postmenopausal osteoporosis, Dr Sabashini Ramchand said initial combination approaches combining two antiresorptive agents had not generally shown significant benefit over monotherapy. “Most ...
Only one combination therapy likely to improve bone health: ANZBMS 2020
By Mardi Chapman
20 Oct 2020